Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab

Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays

Afonso, J.
Lopes, S.
Gonçalves, R.
Caldeira, Paulo
Lago, P.
Sousa, Helena Tavares
Ramos, J.
Gonçalves, A. R.
Ministro, P.
Rosa, I.
Vieira, A. I.
Dias, C. C.
Magro, F.

October 2016

BackgroundTherapeutic drug monitoring is a powerful strategy known to improve the clinical outcomes ...

Comparative study of both versions of an immunoassay commercialized for therapeutic drug monitoring of adalimumab in rheumatoid arthritis

Llinares-Tello, F.
Rosas, Jose
Delás De la Torre, Inmaculada
Valor, Lara
Barber, X.
Senabre, Jose Miguel
Sánchez-Barrioluengo, M

January 2013

[ES] Objetivo: Describir los resultados del estudio comparativo entre las 2 versiones de un inmunoan...

Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

Svenson, M.
Geborek, P.
Saxne, Tore
Bendtzen, K.

January 2007

Objectives. Infliximab is an anti-tumour necrosis factor-alpha (TNF-alpha) mousehuman IgG1/k antibod...

Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab

Llinares-Tello, Francisca
Gomez de Salazar, José Rosas
Senabre Gallego, José Miguel
Santos Soler, Gregorio
Santos Ramírez, Carlos
Salas Heredia, Esteban
Molina García, Juan

October 2012

Llinares-Tello, F.; Gomez De Salazar, JR.; Senabre Gallego, JM.; Santos Soler, G.; Santos Ramírez, C...

Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10<sup>®</sup> to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies

Anne Emmanuelle Berger
Aude Gleizes
Louis Waeckel
Xavier Roblin
Roman Krzysiek
Salima Hacein-Bey-Abina
Alessandra Soriano
Stephane Paul

August 2022

Background. Monitoring of biological TNF inhibitors is a very important tool to guide clinical decis...

Therapeutic Drug Monitoring of Antibody Drugs

Yonezawa, Atsushi

July 2022

In recent years, many antibody drugs that play an important role in the pharmacotherapy of several d...

Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays

Bian, Sumin
Van Stappen, Thomas
Baert, Filip
Compernolle, Griet
Brouwers, Els
Tops, Sophie
Vries, Annick de
Rispens, Theo
Lammertyn, Jeroen
Vermeire, Séverine
Gils, Ann

June 2016

A number of assays are currently available to support therapeutic drug monitoring of adalimumab. A c...

Quantification of infliximab and adalimumab in human plasma by a liquid chromatography tandem mass spectrometry kit and comparison with two ELISA methods

Tron, Camille
Lemaitre, Florian
Bros, Pauline
Goulvestre, Claire
Franck, Benedicte
Mouton, Nicolas
Bagnos, Sandrine
Coriat, Romain
Khoudour, Nihel
Lebert, Dorothee
Blanchet, Benoit

June 2022

International audienceBackground: This study compared the performance of plasma infliximab and adali...

Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine

Gehin, Johanna Elin
Goll, Guro Løvik
Brun, Marthe Kirkesæther
Jani, Meghna
Bolstad, Nils
Syversen, Silje Watterdal

January 2022

Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but a substa...

The new test for monitoring infliximab therapy: From laboratory to clinical practice

De Santis, Elena
Melegari, Alessandra
Bonaguri, Chiara
Sandri, Gilda
Mascia, Maria Teresa
Gaiani, Federica
Pecoraro, Valentina
De Angelis, Gianluigi
Trenti, Tommaso

January 2018

Background: Biological agents for anti-tumor necrosis factor-Î± therapy have revolutionized treatmen...

Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples

Gils, Ann
Van Stappen, Thomas
Dreesen, Erwin
Storme, Ruth
Vermeire, Séverine
Declerck, Paul

April 2016

The availability of an infliximab ELISA for measuring the originator drug Remicade and its biosimila...

New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis

Meroni, Pier Luigi
Cattaneo, Antonino
Valesini, Guido
VALENTINI, GABRIELE
AYALA, FABIO

January 2015

Aim: To assess the putative link between antibody formation to adalimumab, infliximab and etanercept...

Therapeutic drug monitoring (TDM)

Routledge, Philip Alexander
Hutchings, Alun

January 2013

This chapter provides a review of the use of immunoassay in therapeutic drug monitoring. The immunoa...

Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays

Joana Afonso
Helena Tavares de Sousa
Isadora Rosa
João Carvalho
Cláudia Camila Dias
Fernando Magro

September 2017

Background: The commercialization of CT-P13, an infliximab (IFX) biosimilar, has the potential to de...

Validation of a sample pretreatment protocol to convert a drug-sensitive into a drug-tolerant anti-infliximab antibody immunoassay

Van Stappen, Thomas
Brouwers, Els
Vermeire, Séverine
Gils, Ann

February 2017

A meta-analysis revealed that up to 51% of patients treated with infliximab develop anti-drug Abs (A...

Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays

Afonso, J.
Lopes, S.
Gonçalves, R.
Caldeira, Paulo
Lago, P.
Sousa, Helena Tavares
Ramos, J.
Gonçalves, A. R.
Ministro, P.
Rosa, I.
Vieira, A. I.
Dias, C. C.
Magro, F.

October 2016

BackgroundTherapeutic drug monitoring is a powerful strategy known to improve the clinical outcomes ...

Comparative study of both versions of an immunoassay commercialized for therapeutic drug monitoring of adalimumab in rheumatoid arthritis

Llinares-Tello, F.
Rosas, Jose
Delás De la Torre, Inmaculada
Valor, Lara
Barber, X.
Senabre, Jose Miguel
Sánchez-Barrioluengo, M

January 2013

[ES] Objetivo: Describir los resultados del estudio comparativo entre las 2 versiones de un inmunoan...

Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

Svenson, M.
Geborek, P.
Saxne, Tore
Bendtzen, K.

January 2007

Objectives. Infliximab is an anti-tumour necrosis factor-alpha (TNF-alpha) mousehuman IgG1/k antibod...

Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab

Llinares-Tello, Francisca
Gomez de Salazar, José Rosas
Senabre Gallego, José Miguel
Santos Soler, Gregorio
Santos Ramírez, Carlos
Salas Heredia, Esteban
Molina García, Juan

October 2012

Llinares-Tello, F.; Gomez De Salazar, JR.; Senabre Gallego, JM.; Santos Soler, G.; Santos Ramírez, C...

Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10<sup>®</sup> to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies

Anne Emmanuelle Berger
Aude Gleizes
Louis Waeckel
Xavier Roblin
Roman Krzysiek
Salima Hacein-Bey-Abina
Alessandra Soriano
Stephane Paul

August 2022

Background. Monitoring of biological TNF inhibitors is a very important tool to guide clinical decis...

Therapeutic Drug Monitoring of Antibody Drugs

Yonezawa, Atsushi

July 2022

In recent years, many antibody drugs that play an important role in the pharmacotherapy of several d...

Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays

Bian, Sumin
Van Stappen, Thomas
Baert, Filip
Compernolle, Griet
Brouwers, Els
Tops, Sophie
Vries, Annick de
Rispens, Theo
Lammertyn, Jeroen
Vermeire, Séverine
Gils, Ann

June 2016

A number of assays are currently available to support therapeutic drug monitoring of adalimumab. A c...

Quantification of infliximab and adalimumab in human plasma by a liquid chromatography tandem mass spectrometry kit and comparison with two ELISA methods

Tron, Camille
Lemaitre, Florian
Bros, Pauline
Goulvestre, Claire
Franck, Benedicte
Mouton, Nicolas
Bagnos, Sandrine
Coriat, Romain
Khoudour, Nihel
Lebert, Dorothee
Blanchet, Benoit

June 2022

International audienceBackground: This study compared the performance of plasma infliximab and adali...

Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine

Gehin, Johanna Elin
Goll, Guro Løvik
Brun, Marthe Kirkesæther
Jani, Meghna
Bolstad, Nils
Syversen, Silje Watterdal

January 2022

Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but a substa...

The new test for monitoring infliximab therapy: From laboratory to clinical practice

De Santis, Elena
Melegari, Alessandra
Bonaguri, Chiara
Sandri, Gilda
Mascia, Maria Teresa
Gaiani, Federica
Pecoraro, Valentina
De Angelis, Gianluigi
Trenti, Tommaso

January 2018

Background: Biological agents for anti-tumor necrosis factor-Î± therapy have revolutionized treatmen...

Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples

Gils, Ann
Van Stappen, Thomas
Dreesen, Erwin
Storme, Ruth
Vermeire, Séverine
Declerck, Paul

April 2016

The availability of an infliximab ELISA for measuring the originator drug Remicade and its biosimila...

New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis

Meroni, Pier Luigi
Cattaneo, Antonino
Valesini, Guido
VALENTINI, GABRIELE
AYALA, FABIO

January 2015

Aim: To assess the putative link between antibody formation to adalimumab, infliximab and etanercept...

Therapeutic drug monitoring (TDM)

Routledge, Philip Alexander
Hutchings, Alun

January 2013

This chapter provides a review of the use of immunoassay in therapeutic drug monitoring. The immunoa...

Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays

Joana Afonso
Helena Tavares de Sousa
Isadora Rosa
João Carvalho
Cláudia Camila Dias
Fernando Magro

September 2017

Background: The commercialization of CT-P13, an infliximab (IFX) biosimilar, has the potential to de...

Validation of a sample pretreatment protocol to convert a drug-sensitive into a drug-tolerant anti-infliximab antibody immunoassay

Van Stappen, Thomas
Brouwers, Els
Vermeire, Séverine
Gils, Ann

February 2017

A meta-analysis revealed that up to 51% of patients treated with infliximab develop anti-drug Abs (A...

Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays

Afonso, J.
Lopes, S.
Gonçalves, R.
Caldeira, Paulo
Lago, P.
Sousa, Helena Tavares
Ramos, J.
Gonçalves, A. R.
Ministro, P.
Rosa, I.
Vieira, A. I.
Dias, C. C.
Magro, F.

October 2016

BackgroundTherapeutic drug monitoring is a powerful strategy known to improve the clinical outcomes ...

Comparative study of both versions of an immunoassay commercialized for therapeutic drug monitoring of adalimumab in rheumatoid arthritis

Llinares-Tello, F.
Rosas, Jose
Delás De la Torre, Inmaculada
Valor, Lara
Barber, X.
Senabre, Jose Miguel
Sánchez-Barrioluengo, M

January 2013

[ES] Objetivo: Describir los resultados del estudio comparativo entre las 2 versiones de un inmunoan...

Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

Svenson, M.
Geborek, P.
Saxne, Tore
Bendtzen, K.

January 2007

Objectives. Infliximab is an anti-tumour necrosis factor-alpha (TNF-alpha) mousehuman IgG1/k antibod...

Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab

Abstract

Extracted data

Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab

Abstract

Extracted data

Related items

Related items